Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7622 in mild to moderate Alzheimer's Disease
NCT01852110Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-7622 in Alzheimer's disease (AD) (6 arms), sponsored by Merck & Co. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 12 weeks and Number of Participants Experiencing an Adverse Event at 26 weeks. Started Oct 2013; status: terminated.
02
Drugs
MK-7622
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01852110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852110.